Age-Specific Prostate Specific Antigen Cutoffs for Guiding Biopsy Decision in Chinese Population

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Na, Rong ^a,c   Wu, Yishuo ^a,c   Xu, Jianfeng ^a,b,c   Jiang, Haowen ^a,c   Ding, Qiang ^a,c  

^a FUDAN UNIVERSITY   (China)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CHINESE; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; DECISION MAKING; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE STANDARDS; ROC CURVE;

EID: 84879353600     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067585     Document Type: Article

References (29)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127: 2893-2917.
3. Ye DW LC, (2007) Epidemiological trends of prostate cancer:Retrospect and prospect. China Oncology 17: 4.
4. Hsing AW, Tsao L, Devesa SS, (2000) International trends and patterns of prostate cancer incidence and mortality. International Journal of Cancer 85: 60-67.
5. Carter HB, Metter EJ, Wright J, Landis P, Platz E, et al. (2004) Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging. J Natl Cancer Inst 96: 557-558.
6. Fang J, Metter EJ, Landis P, Chan DW, Morrell CH, et al. (2001) Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58: 411-416.
7. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, et al. (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94: 981-990.
8. Fitzpatrick JM, Banu E, Oudard S, (2009) Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 103: 578-587.
9. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, et al. (2010) A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19: 1193-1200.
10. Veltri RW, Miller MC, O'Dowd G J, Partin AW, (2002) Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. Urology 60: 47-52.
11. Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW, (2003) Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 169: 125-129.
12. Park J, Sokoll LJ, Bruzek DJ, Mangold L, Gurganus R, et al. (2003) Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men. Clin Prostate Cancer 2: 173-176.
13. Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, et al. (1996) Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol 155: 1336-1339.
14. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, et al. (1993) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864.
15. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, et al. (1995) Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095.
16. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, et al. (1996) Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335: 304-310.
17. Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, et al. (1998) The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol 82: 231-236.
18. Kao CH, (1997) Age-related free PSA, total PSA and free PSA/total PSA ratios: establishment of reference ranges in Chinese males. Anticancer Research 17: 1361-1365.
19. Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, et al. (2001) EAU guidelines on prostate cancer. Eur Urol 40: 97-101.
20. Wolf JS Jr, (2012) 2012 AUA clinical practice guidelines. Introduction. J Urol 188: 2454.
21. Liu ZY, Sun YH, Xu CL, Gao X, Zhang LM, et al. (2009) Age-specific PSA reference ranges in Chinese men without prostate cancer. Asian J Androl 11: 100-103.
22. Guan M, Sun SL, Xie RH, Huang ZP, Wen SW, et al. (2011) [Age-specific reference ranges for prostate specific antigen in 16 222 Chinese men]. Beijing Da Xue Xue Bao 43: 586-590.
23. Na R, Jiang H, Kim ST, Wu Y, Tong S, et al. (2012) Outcomes and trends of prostate biopsy for prostate cancer in Chinese men from 2003 to 2011. PLoS One 7: e49914.
24. Kalish LA, McKinlay JB, (1999) Serum prostate-specific antigen levels (PSA) in men without clinical evidence of prostate cancer: age-specific reference ranges for total PSA, free PSA, and percent free PSA. Urology 54: 1022-1027.
25. Draisma G, Postma R, Schroder FH, van der Kwast TH, de Koning HJ, (2006) Gleason score, age and screening: modeling dedifferentiation in prostate cancer. International Journal of Cancer 119: 2366-2371.
26. Galen RS, (1982) Application of the predictive value model in the analysis of test effectiveness. Clin Lab Med 2: 685-699.
27. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, et al. (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294: 66-70.
28. Orozco R, O'Dowd G, Kunnel B, Miller MC, Veltri RW, (1998) Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology 51: 186-195.
29. O'Dowd GJ, Miller MC, Orozco R, Veltri RW, (2000) Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology 55: 553-559.